PURPOSE:To prepare an oil-in-water type emulsified composition dispersely stable with passage of time by dissolving hydrogenated lecithin, stevia and polyhydric alcohol by heating at a temperature equal to or higher than the melting point of lecithin and thereafter gradually adding oil thereto under agitation. CONSTITUTION:Polyhydric alcohol, hydrogenated lecithin and stevia are dissolved together...

PURPOSE:To obtain a drug preparation containing plasminogen activation factor originated from human uterus (uTPA), having remarkably improved stability and keeping the stabilizing effect even after freeze-drying, by adding a polyoxyethylene hardened castor oil derivative to uTPA. CONSTITUTION:A polyoxyethylene hardened castor oil derivative is added to uTPA produced by genetic recombination techni...

Disclosed herein are adrenergic compounds represented by the formula wherein m is 0, 1 or 2; R1, R2, R3 are taken from the group consisting of hydrogen, hydroxy, loweralkyl, loweralkoxy, halo, or NHSO2R wherein R is taken from the group consisting of hydrogen, loweralkyl or arylalkyl, provided that R1, R2, R3 cannot simultaneously be hydrogen, and provided that when one of R1, R2, R3 is h...

Novel compounds of the present invention are represented by the general formula (I) wherein R1 is hydrogen atom or amino, R2 is fluorine atom or methoxy, R3 is hydrogen atom or a lower alkyl having 1 to 3 carbon atoms, and n is 0 or 1. The compounds of the general formula (1) exhibit higher antibacterial activity with fewer side-effects than known quinolone antibiotics such as ofloxacin and...

1. Claims for the contracting states : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE New cyclic amine derivatives of general formula see diagramm : EP0224794,P49,F1 wherein A represents a -CH2 -CH2 -, -CH=CH-, see diagramm : EP0224794,P49,F2 or see diagramm : EP0224794,P49,F3 group and B represents a methylene, carbonyl or thiocarbonyl group or A represents a -CO-CO- or see diagramm : EP0224794,P4...

Cognitive deficiencies and/or neurological function deficits and/or mood and/or mental disturbances are treated by the administration of 3,3-disubstituted indolines. The indolines have the formula: wherein: p is 0 or 1; Z is O or S; R is C1-C10 alkyl, C3-C8 cycloalkyl, 2-pyridyl, 3-pyridyl, 4-pyridyl or V, W, X, and Y independently are H, halo, C1-C3 alkyl, OR<1>, NO2, CF3, CN or ...

PURPOSE:To obtain an aqueous enteric coating solution, capable of giving coating films having improved resistance to the first solution with ready separating operation, by using a hydroxycarboxylic acid type cellulose derivative finely pulverized to an average particle diameter within a specific range. CONSTITUTION:An aqueous enteric coating solution containing particles of a water-insoluble hydro...

The novel bicyclic peroxides of the general formula in which R denotes a saturated or partially unsaturated hydrocarbon group having up to 15 carbon atoms or an aryl, heteroaryl, arylcarbonyl or heteroarylcarbonyl group bonded via an alkyl or alkenyl group having up to 7 carbon atoms, have useful pharmacological properties. They especially exhibit a marked effect against the causative o...

A novel process for the manufacture of the optically active lactone of the formula I (3aS,6aR) is described.

Antidiarrheal compositions showing enhanced antidiarrheal activity comprise a non-steroidal anti-inflammatory drug compound and a polymeric hydroabsorptive agent. A patient in need of remedial or preventive treatment of diarrhea symptoms is administered an antidiarrheally effective amount of said antidiarrheal compositions.

Glutarimide derivatives of the formula which are useful antihypertensive and antianxiety agents wherein R1 and R2 each independently represent hydrogen, a 1 to 4 carbon alkyl, a 1 to 4 carbon alkoxy, halogen, nitro, hydroxy SO3H, SO2NH2, and when R1 and R2 are taken together, form a fused phenyl group at the 1,2- or 3,4-positions, with the proviso that when R1 and R2 are identical they each...

NEW MATERIAL:The 2-(5-fluoronicotinoyl)acetic acid derivative of formula I (R<1> is group capable of forming carboxyl-protecting group; R<2> is halogen, hydroxy, 3-aminopyrrolidinyl, piperazinyl, alkoxy, alkylthio, arylthio, alkanesulfonyloxy, or arenesulfonyloxy; X is H or F) and its salt. EXAMPLE:2-(2,4-Difluorophenylamino)-5-fluoro-6-hyroxynicotinoylacetic acid ethyl ester. USE:Intermediate for...

An antibacterial agent of the formula:- or a pharmaceutically acceptable acid addition salt thereof, wherein R is allyl or propargyl.

Pyrazole compounds inhibit aromatase and are useful to prevent or treat estrogen-dependent disease.

A compound of the formula (I) (I) wherein R is a group R1 is hydrogen, phenyl, C1-20 alkyl, C2-8 alkenyl or C2-8 alkynyl each of which may optionally be substituted; or C3-7 cycloalkyl, X is a divalent group -Y-C=C-, and Y is oxygen or sulphur, have antibacterial and/or antimycoplasmal activity.

(A) Bicyclic cpds. of formula (I) and their salts are new; where n = 0 or 1; m = 0-3; X = CH2, O, S, SO, SO2, NH or 1-4C alkylimino; X1 = CH2, O, S, SO or SO2; Y+Y1 = O, or Y = H and Y1 = OH or in-vivo hydrolysable acyloxy; Z = CH2, CHMe, CH2CH2 or CH2CH2CH2; Z1 = CH or N; R = 2-, 3- or 4-pyridyl, 2-, 3-, 4- or 8-quinolyl, 1-, 3- or 4-isoquinolyl, etc , , all opt. mono- or disubstd. R1 = a C-bonde...

Oligomeric esters of the formula I or II I II in which n has a value from 1 to 3, R1 and R2 are divalent organic radicals, at least one of which contains a polyalkylpiperidine radical of the formula III III in which R is hydrogen or C1-C4-alkyl and E and E' are end groups, are prepared by polycondensing a dicarboxylic acid ester with a diol, one of the two compone...

Novel pyridazinamine derivatives of formula wherein R<1> is hydrogen, C1-6alkyl, halo, hydroxy, mercapto, trifluoromethyl, amino, mono or di(C1-6alkyl)amino, cyano, C1-6alkyloxy, aryloxy, arylC1-6alkyloxy, C1-6alkylthio, arylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, arylsulfinyl, aryllsulfonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyl or aryl; R<2> and R<3> each independently are hydrogen...

A controlled-release pharmaceutical preparation of 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine. The controlled-release preparation is in the form of rectal suppository containing 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine. Further the controlled-release is prepared by implanting 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine in an oleaginous base.